Targets › PRKACA
2 programs from 2 companies in 5 trials: 5 Phase 1; Oncology; next expected readout Jan 2027.
Phosphorylates a large number of substrates in the cytoplasm and the nucleus. Phosphorylates CDC25B, ABL1, NFKB1, CLDN3, histone H1.4 (H1-4), PSMC5/RPT6, PJA2, RYR2, RORA, SLC6A6, SOX9, UHRF1 and VASP. Regulates the abundance of compartmentalized pools of its regulatory subunits through phosphorylation of PJA2 which binds and ubiquitinates these subunits, leading to their subsequent proteolysis. (UniProt, P17612)
Open in Phaseline: the race on PRKACA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University Hospital Tuebingen | Fusion-VAC-XS15 DNAJB1-PRKACA fusion peptide vaccine with TLR1/2 agonist | DNAJB1, PRKACA | Phase 1 | Fibrolamellar Hepatocellular Carcinoma; Fibrolamellar Hepatocellular Carcinoma (FLC) | Jan 2027 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | DNAJB1-PRKACA Peptide Vaccine Peptide vaccine targeting DNAJB1-PRKACA fusion kinase | DNAJB1, PRKACA | Phase 1 | NSCLC Stage IV; Fibrolamellar Hepatocellular Carcinoma (FLC); Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) | Jul 2027 |
Fibrolamellar Hepatocellular Carcinoma (FLC) (2) NSCLC Stage IV (1) Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) (1) Fibrolamellar Hepatocellular Carcinoma (1)
mixed (1), other (1)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) University Hospital Tuebingen (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.